Skip Navigation


JAC Advance Access originally published online on November 10, 2004
Journal of Antimicrobial Chemotherapy 2004 54(6):1152-1154; doi:10.1093/jac/dkh490
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/6/1152    most recent
dkh490v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bergshoeff, A. S.
Right arrow Articles by Burger, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergshoeff, A. S.
Right arrow Articles by Burger, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.6 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children

Alina S. Bergshoeff1,2, Pieter L. A. Fraaij3, Corrien Verweij1,2, Annemarie M. C. van Rossum3, Gwenda Verweel3, Nico G. Hartwig3, Ronald de Groot3 and David M. Burger1,2,*

1 Department of Clinical Pharmacy, University Medical Center, Nijmegen; 2 Nijmegen University Center for Infectious Diseases, Nijmegen; 3 Department of Pediatrics, Erasmus MC/Sophia, Rotterdam, The Netherlands

* Correspondence address. Department of Clinical Pharmacy, University Medical Center, PO Box 9101, 533 KF, 6500 HB Nijmegen, The Netherlands. Tel: +31-24-3616405; Fax: +31-24-3540331; Email: d.burger{at}akf.umcn.nl

Objectives: Zidovudine is often administered every 12 h in HIV-infected children, but so far no pharmacokinetic data are available for the administration of this agent every 12 h. We have evaluated the plasma pharmacokinetics of zidovudine administered every 8 h versus every 12 h in HIV-1-infected children.

Methods: In HIV-1-infected children who switched from zidovudine every 8 h to every 12 h, a pharmacokinetic curve was recorded both before and after the switch. Zidovudine plasma levels were measured by HPLC. Pharmacokinetic parameters were calculated by non-compartmental methods.

Results: Six HIV-1-infected children [median age (range) 7.8 (2.5–13.4) years] were included. In these patients, geometric mean ratios of AUC0–24 and Cmax for zidovudine every 12 h versus every 8 h were not significantly different from 1.0.

Conclusions: The plasma pharmacokinetic parameters of zidovudine taken every 8 h and every 12 h were not significantly different and therefore suggest bioequivalence of these two dose frequencies.

Keywords: pharmacokinetics , paediatrics , pharmacology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.